RESUMO
The development of chemotherapeutic dug resistance hinders the clinical treatment of cancer. MicroRNAs (miRNAs/miRs) have been revealed to serve essential roles in the drug resistance of numerous types of cancer. miR1395p was previously reported to be associated with cisplatin (DDP) sensitivity in human nasopharyngeal carcinoma cells and colorectal cancer cells. However, the effect and underlying mechanism of miR1395p in DDP sensitivity in nonsmall cell lung cancer (NSCLC) cells has not yet been fully elucidated. In the present study, the expression of miR1395p and Homeobox protein HoxB2 (HOXB2) in NSCLC tissues was examined by reverse transcriptionquantitative polymerase chain reaction (RTqPCR) and western blotting. Subsequently, the effect of miR1395p on the DDP sensitivity of NSCLC cells in vitro was investigated. Cell proliferation was examined using a Cell Counting Kit8 assay. Western blotting was used to evaluate the protein expression of HOXB2, phosphorylated (p)PI3K, pAKT, caspase3 and cleavedcaspase3, and RTqPCR was used to evaluate the expression of miR1395p, and the mRNA expression levels of HOXB2, PI3K, AKT and caspase3. The apoptotic rate of the cells was detected using flow cytometry. miR1395p expression in NSCLC tissues was shown to be significantly lower compared with that in adjacent tissues. Additionally, miR1395p increased cell apoptosis and inhibited NSCLC cell proliferation induced by DDP in vitro via modulating the PI3K/AKT/caspase3 signaling pathway. Furthermore, HOXB2 was identified to be a target of miR1395p, and miR1395p was revealed to sensitize NSCLC cells to DDP via the targeting of HOXB2. Taken together, the results of the present study demonstrated that regulating the expression of miR1395p could provide a novel approach to reverse DDP resistance and increase chemosensitivity in the treatment of NSCLC.
Assuntos
Apoptose/efeitos dos fármacos , Carcinoma Pulmonar de Células não Pequenas/metabolismo , Proliferação de Células/efeitos dos fármacos , Cisplatino/farmacologia , Proteínas de Homeodomínio/metabolismo , Neoplasias Pulmonares/metabolismo , MicroRNAs/metabolismo , Proteínas de Neoplasias/metabolismo , RNA Neoplásico/metabolismo , Fatores de Transcrição/metabolismo , Células A549 , Idoso , Carcinoma Pulmonar de Células não Pequenas/tratamento farmacológico , Carcinoma Pulmonar de Células não Pequenas/genética , Carcinoma Pulmonar de Células não Pequenas/patologia , Feminino , Proteínas de Homeodomínio/genética , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/genética , Neoplasias Pulmonares/patologia , Masculino , MicroRNAs/genética , Pessoa de Meia-Idade , Proteínas de Neoplasias/genética , RNA Neoplásico/genética , Fatores de Transcrição/genéticaRESUMO
PURPOSE: To evaluate the efficacy and oncologic outcomes of transoral laser microsurgery (TLM) for recurrent laryngeal carcinoma after previous treatment. MATERIALS AND METHODS: A systematic search in PubMed was performed using mesh word for "laryngeal cancer," crossed with "recurrent," and "TLM." The primary endpoints, including overall survival (OS) rate, local control rate, and disease-specific survival (DSS) were summarized using RevMan software. Adverse events and complications were recorded if reported. RESULTS: The pooled odds ratios (ORs) for main outcomes, including local control, 5-year OS, and DSS were 3.08 (95% confidential indexed [95% CI], 1.88-5.05), 2.29 (95% CI, 1.42-3.67), and 5.05 (95% CI, 2.75-9.27), respectively. The pooled OR for functional outcome, larynx preservation, was 3.82 (95% CI, 2.46-5.94), whereas the pooled risk difference of local recurrence was 45% (95% CI, 26-64%). CONCLUSIONS: It seems that TLM is an effective option for recurrent laryngeal cancer with regard to the high incidence of OS, local control, and especially organ preservation. However, more prospective studies are needed to confirm its efficiency.